THE INCREASED RISK OF RANDOM BLOOD GLUCOSE, BODY MASS INDEX AND ABDOMINAL CIRCUMFERENCE IN THE SCHIZOPHRENIC PATIENTS USING CLOZAPINE AND QUETIAPINE

L. Hidayah, E. Darmawan, Santi Yuliani
{"title":"THE INCREASED RISK OF RANDOM BLOOD GLUCOSE, BODY MASS INDEX AND ABDOMINAL CIRCUMFERENCE IN THE SCHIZOPHRENIC PATIENTS USING CLOZAPINE AND QUETIAPINE","authors":"L. Hidayah, E. Darmawan, Santi Yuliani","doi":"10.55047/comorbid.v1i1.67","DOIUrl":null,"url":null,"abstract":"\nThe use of atypical antipsychotics often causes an increase in blood glucose levels, body mass index (BMI) and abdominal circumference. This study aims to identify the increased risk of random blood glucose, BMI and abdominal circumference in the schizophrenic patients using clozapine and quetiapine. This cohort study involved 35 schizophrenic patients (19 patients used clozapine and 16 patients used quetiapine). The measurement of random blood glucose BMI and abdominal circumference was done in the zero month, the first month and the second month. The average of random blood glucose, BMI and abdominal circumference were analyzed using Wilcoxon and Chi-square. In the use of clozapine, there is a significant increase in the average of random blood glucose between the first month and the second month (p=0.1) with the difference of 6.37 mg/dl, there is an increase average in BMI between the first month and the second month (p=0.03) with the difference of 0.18 kg/m² and an average increase in abdominal circumference between the zero month and the first month (p=0.04) with the difference of 1.47 cm, between the first month and the second month (p=0.02) with the difference of 1.94 cm. In the use of quetiapine, a significant increase in abdominal circumference between the first month and the second month (p=0.02) with the difference 1.38 cm. The use of clozapine has more risk in increasing random blood glucose (OR 2.00: CI 95% 0.41-9.76), BMI (OR 2.78: CI 95% 0.69-11.10) and abdominal circumference (OR 3.61: CI 95% 0.89-14.64) compared to the use of quetiapine. The use of clozapine has more risk in increasing blood glucose, BMI and abdominal circumference compared to the use of quetiapine. \n \n \n  \n \n \n  \n","PeriodicalId":19772,"journal":{"name":"PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55047/comorbid.v1i1.67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The use of atypical antipsychotics often causes an increase in blood glucose levels, body mass index (BMI) and abdominal circumference. This study aims to identify the increased risk of random blood glucose, BMI and abdominal circumference in the schizophrenic patients using clozapine and quetiapine. This cohort study involved 35 schizophrenic patients (19 patients used clozapine and 16 patients used quetiapine). The measurement of random blood glucose BMI and abdominal circumference was done in the zero month, the first month and the second month. The average of random blood glucose, BMI and abdominal circumference were analyzed using Wilcoxon and Chi-square. In the use of clozapine, there is a significant increase in the average of random blood glucose between the first month and the second month (p=0.1) with the difference of 6.37 mg/dl, there is an increase average in BMI between the first month and the second month (p=0.03) with the difference of 0.18 kg/m² and an average increase in abdominal circumference between the zero month and the first month (p=0.04) with the difference of 1.47 cm, between the first month and the second month (p=0.02) with the difference of 1.94 cm. In the use of quetiapine, a significant increase in abdominal circumference between the first month and the second month (p=0.02) with the difference 1.38 cm. The use of clozapine has more risk in increasing random blood glucose (OR 2.00: CI 95% 0.41-9.76), BMI (OR 2.78: CI 95% 0.69-11.10) and abdominal circumference (OR 3.61: CI 95% 0.89-14.64) compared to the use of quetiapine. The use of clozapine has more risk in increasing blood glucose, BMI and abdominal circumference compared to the use of quetiapine.    
使用氯氮平和喹硫平的精神分裂症患者随机血糖、体重指数和腹围的风险增加
非典型抗精神病药物的使用通常会导致血糖水平、身体质量指数(BMI)和腹围增加。本研究旨在确定使用氯氮平和喹硫平的精神分裂症患者随机血糖、BMI和腹围增加的风险。这项队列研究涉及35名精神分裂症患者(19名患者使用氯氮平,16名患者使用喹硫平)。随机测定血糖、BMI和腹围,分别于第0个月、第1个月和第2个月测定。随机血糖、BMI和腹围平均值采用Wilcoxon和卡方分析。使用氯氮平后第一个月与第二个月随机血糖平均值显著升高(p=0.1),差值为6.37 mg/dl;第一个月与第二个月BMI平均值升高(p=0.03),差值为0.18 kg/m²;第0个月与第一个月腹围平均值升高(p=0.04),差值为1.47 cm;第1个月与第2个月比较(p=0.02),差异为1.94 cm。在使用喹硫平时,第1个月和第2个月的腹围明显增加(p=0.02),差异为1.38 cm。与使用喹硫平相比,氯氮平增加随机血糖(OR 2.00: CI 95% 0.41-9.76)、BMI (OR 2.78: CI 95% 0.69-11.10)和腹围(OR 3.61: CI 95% 0.89-14.64)的风险更高。与喹硫平相比,氯氮平增加血糖、BMI和腹围的风险更大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信